In the ongoing battle against COVID-19, doctors are treating severely ill patients with various drugs, one of which is tocilizumab, which blocks the cytokine interleukin-6 (L-6) receptor. For the first time in the United States, researchers at the University of North Carolina report that the drug did not show clear benefit to 11 severely ill patients and should be used with caution. (UNC.edu)
